A pilot study of Auron Misheil Therapy in patients with advanced cervical cancer: Tumor response and its correlation with clinical benefit response, and preliminary quality of life data

Oncology Reports

Volumn 22, Issue 4, 2009, Pages 877-883

  Scheele, Jürgen ^b,c,d   Niazi, Faiz ^b   Drevs, Joachim ^e   Diergarten, Klaus ^b   Toure, Papa ^a  

^a Centre Hospitalier Universitaire Aristide Le Dantec de Dakar   (Senegal)

^b Auron Healthcare GmbH   (Germany)

^c Department of Pharmacology I ^*  (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e Tumorklinik Sanafontis   (Germany)

Author keywords

Auron mishiel therapy; Cervical cancer; Quality of life

Indexed keywords

CHAMOMILE; CHLORPHENIRAMINE; INSULIN; INTERLEUKIN 6;

ADULT; ADVANCED CANCER; ANOREXIA; ARTICLE; AURON MISHEIL THERAPY; BLOOD PRESSURE; BODY WEIGHT; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CORRELATION ANALYSIS; CYTOKINE RELEASE; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG FEVER; DRUG MIXTURE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; ERYTHEMA; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER CORE QUALITY OF LIFE QUESTIONNAIRE; FEMALE; GASTROINTESTINAL SYMPTOM; GENITAL TRACT INFECTION; HUMAN; HYPOGLYCEMIA; IMMUNE RESPONSE; INJECTION SITE PAIN; INJECTION SITE SWELLING; LABORATORY TEST; MALARIA; OPEN STUDY; PAIN ASSESSMENT; PHYSICAL PERFORMANCE; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SIDE EFFECT; URINARY TRACT INFECTION; UTERINE CERVIX CANCER; VITAL SIGN; VOMITING;

ADULT; CALCIUM; CHLORPHENIRAMINE; FEMALE; HUMANS; INSULIN; MIDDLE AGED; NEOPLASM STAGING; PILOT PROJECTS; PLANT EXTRACTS; QUALITY OF LIFE; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 70350371076     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000512     Document Type: Article

References (24)

1. Institute for Experimental Oncology, Oncotest GmbH, Am Flughafen 12-14, 79108, Freiburg, Germany: In vivo evaluation of Auron-Misheil-Medicine in three different murine tumor models. Protocol No. P82G, (8th December, 2003).
2. Bolli S: Die echte Kamille. Phytotherapie 2: 13-17, 2003.
3. Hudson EA, Dinh PA, Kokubun T, Simmonds MJ and Gescher A: Characterization of potentially chemopreventive phenols in extracts of brown rice that inhibit the growth of human breast and colon cancer cells. Cancer Epidemiol Biomarkers Prev 9: 1163-1170, 2000.
4. Chiang LC, Chiang W, Chang MY, Ng LT and Lin CC: Antileukemic activity of selected natural products in Taiwan. Am J Chin Med 31: 37-46, 2000.
5. Ogiwara T, Satoh K, Kadoma Y, et al: Radical scavenging activity and cytotoxicity of ferulic acid. Anticancer Res 22: 2711-2717, 2002.
6. Mori H, Kawabata K, Matsunaga K, et al: Chemopreventive effects of coffee bean and rice constituents on colorectal carcinogenesis. Biofactors 12: 101-105, 2000.
7. Robinson JB, Singh D, Bodurka-Bevers DC, Wharton JT, Gershenson DM and Wolf JK: Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecol Oncol 82: 550-558, 2001.
8. Cameron LB: Neuropsychotic drugs as adjuncts in the treatment of cancer pain. Oncology 6: 65-72, 1992.
9. Medina MA, Garcia de Veas R, Morata P, Lozano J and Sánchez-Jiménez FM: Chlorpheniramine inhibits the synthesis of ornithine decarboxylase and the proliferation of human breast cancer cell lines. Breast Cancer Res Treat 35: 187-194, 1995.
10. Gómez-Fabre PM, de Pedro E, Medina MA, Nunez de Castro I and Márquez J: Polyamine contents of human breast cancer cell treated with the cytotoxic agents chlorpheniramine and dihydrodidemnin B. Cancer Lett 113: 141-144, 1997.
11. Wargovich MJ, Jiminez A, McKee K, et al: Efficacy of potential chemopreventive agents on rat colon aberrant crypt formation and progression. Carcinogenesis 21: 1149-1155, 2000.
12. Suessbrich H, Waldegger S, Lang F and Busch AE: Blockade of HERG channels expressed in Xenopus oocytes by the histamine-receptor antagonists terfenadine and astemizole. FEBS Lett 385: 77-80, 1996.
13. Crociani O, Guasti L, Balzi M, et al: Cell cycle-dependent expression of HERG1 and HERG1B isoforms in tumor cells. J Biol Chem 278: 2947-2955, 2003.
14. Argilés JM and Lopéz-Soriano FJ: Why do cancer cells have such a high glycolytic rate? Med Hypotheses 32: 151-155, 1990.
15. Younes RN and Noguchi Y: Pathophysiology of cancer cachexia. Rev Hosp Clin Fac Med Sao Paulo 55: 181-193, 2000.
16. Ayre SG, Garcia y Bellon DP and Garcia DP J: Insulin, chemotherapy, and the mechanisms of malignancy: the design and the demise of cancer. Med Hypotheses 55: 330-334, 2000.
17. Lasalvia-Prisco E, Cucchi S, Vázquez J, Lasalvia-Galante E, Golomar W and Gordon W: Insulin-induced enhancement of antitumoral response to methotrexate in breast cancer patients. Cancer Chemother Pharmacol 53: 220-224, 2004.
18. Pearlstone DB, Wolf RF, Berman RS, Burt M and Brennan MF: Effect of systemic insulin on protein kinetics in postoperative cancer patients. Ann Surg Oncol 1: 321-332, 1994.
19. Minn H, Nuutila P, Lindholm P, Ruotsalainen U, Bergman J, Teras M and Knuuti MJ: In vivo effects of insulin on tumor and skeletal muscle glucose metabolism in patients with lymphoma. Cancer 73: 1490-1498, 1994.
20. Costelli P, Tessitore L, Batetta B, et al: Alterations of lipid and cholesterol metabolism in cachectic tumor-bearing rats are prevented by insulin. J Nutr 129: 700-706, 1999.
21. Lundholm K, Körner U, Gunnebo L, Sixt-Ammilon P, Fouladiun M, Daneryd P and Bosaeus I: Insulin treatment in cancer cachexia: effects on survival, metabolism and physical functioning. Clin Cancer Res 13: 2699-2706, 2007.
22. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors, European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
23. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365-376, 1993.
24. Scheele J, Drevs J, Diergarten K and Niazi FR: A Phase I double-blind, randomized, placebo-controlled, ascending dose, parallel group trial for the assessment of the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics of single doses of AMT (Auron Misheil Therapy) in healthy male subjects. Int J Pharmac Therap (In press).